Enable Injections, Inc., a Cincinnati, OH-based developer of advanced wearable large volume injectors for subcutaneous delivery of biologics and high volume drugs, closed a $30M Series A financing.
The round was led by ORI Healthcare Fund with participation from CincyTech, Cincinnati Children’s Hospital, CintriFuse and Ohio Innovation Fund.
The company intends to use the funds to commercialize its patient-focused drug delivery product, the Enable Injector.
Founded in February 2010 and led by Michael Hooven, President and CEO, Enable Injections develops and manufactures wearable devices that allow patient self-administration of large volume/high viscosity drugs for pharmaceutical and biotechnology industry investigational use.
The Enable body-worn injector adheres to the body during treatment, delivering biologic doses as large as 50mL. Used at home or work, it offers an alternative to intravenous infusions in a healthcare setting and is expected to lower overall healthcare costs.